Company Description
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings.
The company’s lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit.
It is also developing LTX-608, a lyophilized vial containing nafamostat for IV infusion for disseminated intravascular coagulation, acute respiratory distress syndrome, acute pancreatitis, and an anti-viral treatment; Fedsyra, an ephedrine pre-filled syringe for injection; and a phenylephrine pre-filled syringe for injection.
The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024.
The company was incorporated in 2005 and is headquartered in San Mateo, California.
| Country | United States |
| Founded | 2005 |
| IPO Date | Feb 14, 2011 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 12 |
| CEO | Vincent Angotti |
Contact Details
Address: 1850 Gateway Drive, Suite 175 San Mateo, California 94404 United States | |
| Phone | 650 216 3500 |
| Website | talphera.com |
Stock Details
| Ticker Symbol | TLPH |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001427925 |
| CUSIP Number | 00444T209 |
| ISIN Number | US00444T2096 |
| Employer ID | 41-2193603 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Vincent J. Angotti | Chief Executive Officer and Director |
| Raffi Mark Asadorian | Chief Financial Officer |
| Anil N. Dasu | Chief Engineering Officer |
| Dr. Shakil Aslam M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 29, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 29, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 1, 2026 | EFFECT | Notice of Effectiveness |
| Apr 1, 2026 | 424B7 | Filing |
| Mar 30, 2026 | UPLOAD | Filing |
| Mar 25, 2026 | S-3 | Registration statement under Securities Act of 1933 |
| Mar 23, 2026 | 10-K | Annual Report |
| Mar 23, 2026 | 8-K | Current Report |
| Mar 16, 2026 | 8-K | Current Report |
| Mar 13, 2026 | 8-K | Current Report |